- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| TURN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Turn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.09. | Lucid Capital Markets initiates Turn Therapeutics stock with buy rating | 5 | Investing.com | ||
| 23.09. | Turn Therapeutics auf dem Stifel Forum: Juckreiz-Score als Schlüssel für Studiendesign | 2 | Investing.com Deutsch | ||
| 09.09. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.08. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Turn Therapeutics Inc. GAAP EPS of -$0.20 | 3 | Seeking Alpha | ||
| 12.08. | Turn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 28.07. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | Turn Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Turn Therapeutics: Positive Studiendaten zu Ekzem-Medikament treiben Aktie an | 3 | Investing.com Deutsch | ||
| 01.06. | Turn Therapeutics reports interim phase 2 data for eczema drug | 2 | Investing.com | ||
| 27.05. | Turn Therapeutics publishes GX-03 dermatitis study results | 1 | Investing.com | ||
| 27.05. | Turn Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.05. | Turn Therapeutics Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 18.05. | Turn Therapeutics appoints former FDA chief Stephen Hahn | 3 | Investing.com | ||
| 11.05. | Turn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Turn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates | 318 | GlobeNewswire (Europe) | Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply... ► Artikel lesen | |
| 04.11.25 | Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications | 225 | GlobeNewswire (Europe) | LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies... ► Artikel lesen | |
| 30.10.25 | Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline | 216 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics (Nasdaq: TTRX) ("Turn" or the "Company"), a clinical-stage biotechnology company developing next-generation dermatology... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 15,778 | +1,41 % | Viatris Inc.: Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies | Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International... ► Artikel lesen | |
| SYNBIOTIC | 0,771 | -3,50 % | Viome Acquires Solaria Bio To Expand Into Clinically Validated Synbiotics And Medical Foods | ||
| ORGANIGRAM GLOBAL | 0,812 | -4,36 % | Organigram Global Inc.: Organigram Global treibt die Integration der Sanity Group unter einer einheitlichen globalen Betriebsstruktur voran | Führung, operatives Geschäft und Marktentwicklung werden über eine globale Plattform aufeinander abgestimmt, die Kanada mit Deutschland und anderen wichtigen internationalen Märkten verbindet
Die... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 6,626 | +2,41 % | Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report | ||
| ORAMED PHARMACEUTICALS | 3,695 | 0,00 % | Oramed Pharmaceuticals Inc.: Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet | Significant Appreciation in Alpha Tau (NASDAQ: DRTS) Position (up ~$128 Million)
Scilex (NASDAQ: SCLX) Loan Substantially Repaid
Total Cash and Assets Build... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 9,960 | -0,90 % | SELLAS Life Sciences Group Inc mit PAUKENSCHLAG: Folgt jetzt der nächste Kursrutsch? - Unbedingt noch vor Börsenschluss lesen! | ||
| OPKO HEALTH | 1,210 | -0,82 % | OPKO HEALTH, INC. - 8-K, Current Report | ||
| XORTX THERAPEUTICS | 1,805 | +13,38 % | XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why | ||
| SOLIGENIX | 0,346 | 0,00 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results | PRINCETON, N.J., Aug. 7, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| OPUS GENETICS | 3,880 | -2,51 % | Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff? | ||
| TALPHERA | 0,940 | -2,59 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 4,368 | +1,30 % | Citizens reiterates Savara stock rating on Molbreevi launch outlook | ||
| SCYNEXIS | 3,815 | +1,73 % | SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) | • SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated • Phase 2 proof-of-concept study in patients with ADPKD remains... ► Artikel lesen | |
| PROTHENA | 7,612 | -0,99 % | PROTHENA CORP PUBLIC LTD CO - 8-K, Current Report | ||
| WAVE LIFE SCIENCES | 3,155 | +2,10 % | H.C. Wainwright bestätigt Kaufempfehlung für Wave Life Sciences |
Das Unternehmen TURN THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 11,450 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TURN THERAPEUTICS INC finden Sie auf Wallstreet Online.